European Journal of Cancer

The changing concepts in treating breast cancer
pp. 3-3(1)
Author: Veronesi U.

Diet and breast cancer: Lessons from experimental studies
pp. 3-3(1)
Author: Snyderwine E.G.

Prevention of breast cancer
pp. 3-3(1)
Authors: Costa A.; Decensi A.

Experimental pathology and breast cancer genetics: Looking at malignant and premalignant tissues using new technologies
pp. 3-3(1)
Authors: Osin P.; Shipley J.; Liu Y.J.; Crook T.; Gusterson B.A.

Biology of breast cancer risk and prognosis
pp. 4-4(1)
Authors: Pollak M.; Hankinson S.

Determination of clinical utility of tumor markers: A tumor marker utility grading system
pp. 4-4(1)
Author: Hayes D.F.

Hypothesis and practice: Are there several types of treatment for DCIS?
pp. 4-4(1)
Author: Silverstein M.J.

Shifting knowledge on in situ carcinomas: The pathologist's view
pp. 4-4(1)
Author: Schnitt S.J.

The axilla; To clear or not to clear? That is the question!
pp. 5-5(1)
Author: Blichert-Toft M.

The axilla; To clear or not to clear? That is the question!
pp. 5-5(1)
Author: Veronesi U.

Pre-surgical chemotherapy
pp. 5-5(1)
Author: Margolese R.

Integration of plastic surgery in the course of breast cancer surgery to improve final cosmetic result and radicality of tumor excision
pp. 5-5(1)
Author: Petit J.-Y.

Preoperative therapy (PROP) for breast cancer
pp. 5-6(2)
Author: Fisher B.

Is primary chemotherapy useful in all patients?
pp. 6-6(1)
Authors: Scholl S.; Beuzeboc P.; Asselain B.; Pierga J.-Y.; Pouillart P.

How to combine radiation (RT) and systemic (ST) therapies
pp. 6-6(1)
Author: Harris J.R.

Novel approaches using radiation techniques
pp. 6-6(1)
Author: Rutqvist L.E.

The molecular biology of the estrogen receptor (ER) aids in the understanding of tamoxifen resistance and breast cancer prevention with raloxifene
pp. 6-7(2)
Author: Jordan V.C.

Aromatase inhibitors and their role in the adjuvant treatment strategy
pp. 7-7(1)
Author: Coombes R.C.

GNRH analogues and ovarian ablation: How to integrate in the adjuvant strategy
pp. 7-7(1)
Author: Pritchard K.I.

Putting the taxanes to work: Open questions
pp. 7-7(1)
Authors: Conte P.F.; Del Mastro L.

Putting the taxanes to work
pp. 7-8(2)
Authors: Gianni L.; Capri G.; Valagussa P.; Bonadonna G.

Continuous infusional chemotherapy as pre-operative and as adjuvant treatment in early breast cancer
pp. 8-8(1)
Author: Smith I.E.

Tailored therapy to equal toxicity: Is it possible?
pp. 8-8(1)
Authors: SBG 9401 Study; Bergh J.

Anti angiogenesis therapy and strategies
pp. 8-8(1)
Author: Harris A.L.

Dose intensity and dose density
pp. 8-8(1)
Authors: Piccart M.J.; Biganzoli L.; Di Leo A.

CEF versus CMF in premenopausal women - Recent update
pp. 9-9(1)
Authors: Levine M.; Bramwell V.; Pritchard K.; Shepherd L.

New developments in high-dose chemotherapy for breast cancer
pp. 9-9(1)
Author: Basser R.

Quality of life assessment in the adjuvant setting: Is it relevant?
pp. 9-9(1)
Authors: International Breast Cancer Study Group IBCSG; Gelber R.D.; Gelber S.; Bonetti M.; Goldhirsch A.

Quality of life measurements in the IBCSG: Past, present and future
pp. 9-9(1)
Authors: Hurny C.; Bernhard J.; Coates A.

Impact of different adjuvant therapy strategies on quality of life (QOL) in breast cancer survivors (BCS)
pp. 9-10(2)
Authors: Ganz P.A.; Rowland J.; Meyerowitz B.E.; Desmond K.

North American adjuvant breast cancer trials
pp. 10-10(1)
Author: Abrams J.S.

Clinical research around the world: IBCSG trials
pp. 10-10(1)
Author: Coates A.

Scandinavian/nordic adjuvant trials in breast cancer
pp. 10-10(1)
Author: Mouridsen H.T.

EORTC and big trials
pp. 10-11(2)
Authors: Breast International Group; Piccart M.J.; Biganzoli L.; Goldhirsch A.

Review of Italian breast cancer study group (GROCTA) trials
pp. 11-11(1)
Authors: Boccardo F.; Rubagotti A.; Amoroso D.

Review on current trials of the German adjuvant breast cancer group (GABG)
pp. 11-11(1)
Author: Kaufmann M.

Epidemiology and adjuvant therapy in early breast cancer: A prospective randomised study of 300 Indian patients
pp. 15-15(1)
Authors: Behgal K.S.; Rath G.K.; Julka P.K.; Raina V.; Shukla N.K.

Cost of adjuvant chemotherapy (CT) with CMF and tamoxifen in breast cancer (BC)
pp. 15-15(1)
Authors: Abdyldaev R.A.; Abdyldaev T.A.

The effect of medical information on womens opinion about breast cancer
pp. 15-15(1)
Authors: Tschurtschenthaler G.; Oppitz P.; Hammer J.; Flink P.; Fridrik M.; Michlmayr G.

Ought the impact of different types of consumer involvement in various research activities (commissioning, trial protocol planning, Cochrane research reviews, etc.) be evaluated?
pp. 15-15(1)
Author: Thornton H.

Time trends in systemic adjuvant treatment of early-stage node-negative breast cancer in Quebec
pp. 15-16(2)
Authors: Hebert-Croteau N.; Brisson J.; Latreille J.; Gariepy G.

The breast-cancer susceptibility genes association to epidermal growth factor receptor (EGFR) & to oncogenes
pp. 16-16(1)
Author: Hakim A.A.

BRCA1 and BRCA2 germline mutations in early-onset breast carcinoma patients
pp. 16-16(1)
Authors: Conti A.R.; De Benedetti M.V.G.; Stagi L.; Mondini P.; Pasini B.; Pensotti V.; Spatti G.B.; Rilke F.; Pierotti M.A.; Radice P.

High rate of one specific haplotype in the 13q12-13 region in breast cancer
pp. 16-16(1)
Authors: Silva J.M.; Dominguez G.; Gonzalez R.; Garcia J.M.; Corbacho C.; Villanueva M.J.; Provencio M.; Espana P.; Bonilla F.

High risk breast/ovarian cancer families: Genetic counselling, testing and early cancer detection program
pp. 16-17(2)
Authors: Beckmann M.W.; Niederacher D.; Cho J.Y.; An H.X.; Kuschel B.; Achnoula M.; Goecke T.O.; Bodden-Heidrich R.; Schnurch H.G.; Bender H.G.

Multistep carcinogenesis of sporadic breast cancer
pp. 17-17(1)
Authors: Schnurch H.G.; Niederacher D.; An H.X.; Ellenberger I.; van Roeyen C.R.C.; Cho J.Y.; Beckmann M.W.

Loss of retinoic acid receptor expression in breast cancer and morphopogically normal adjacent tissue but not in the normal breast tissue distant from the cancer
pp. 17-17(1)
Authors: Widschwendter M.; Berger J.; Daxenbichler G.; Widschwendter A.; Zeimet A.G.; Schrocksnadel H.; Dapunt O.

In vitro cultivation of human mammary epithelial cancer cells. Study of their phenotypic characteristics and biologic behavior
pp. 17-17(1)
Authors: Saxena S.; Jain A.K.; Pandey K.K.

Involvement of plasminogen activator inhibitor PAI-1 in in vitro growth of human breast cancer cell lines
pp. 17-18(2)
Authors: Prifti S.; Fersis N.; Sillem M.; Szekelyi M.; Runnebaum B.; Bastert G.

Adjuvant tamoxifen treatment in breast cancer induces no activation of blood coagulation
pp. 18-18(1)
Authors: Oberhoff C.; Winkler U.H.; Schindler A.E.

Blood coagulation and fibrinolysis after oral or intravenous cyclophosphamide containing adjuvant CMF-chemotherapy
pp. 18-18(1)
Authors: Oberhoff C.; Winkler U.H.; Schindler A.E.

Adjuvant Goserelin depot in premenopausal women with early breast cancer: Ovarian function, bone mineral density and survival. Preliminary data
pp. 18-18(1)
Authors: De Matteis A.; D'Aiuto G.; Landi G.; Nuzzo F.; Labonia V.; Montedoro D.; Rossi E.; Capasso I.; Pizzorusso M.

Weight gain associated with breast cancer adjuvant chemotherapy
pp. 18-19(2)
Authors: Fried G.; Drumea K.; Yereslav N.; Vizel B.; Haim N.

Plasma lipids and lipoproteins in breast cancer women in relation to body mass index (BMI) and fat distribution (WHR)
pp. 19-19(1)
Authors: Dziewulska-Bokiniec A.; Wojtacki J.; Wroblewska M.; Skokowski J.

Value of seric cholesterol in the prognosis and treatment of breast cancer
pp. 19-19(1)
Authors: Lazo R.; Lopez S.

Extensive screening of women with high risk node positive breast cancer: An update
pp. 19-19(1)
Authors: Crump M.; Abraham R.; Goss P.; Arts K.

High-risk breast cancer patients (>9 involved nodes) MO at conventional staging procedures: Additional findings suggesting M1-status
pp. 19-19(1)
Authors: Mohrmann S.; Nitz U.; Kuschel B.; Adomeit A.; Dall P.; Dobrovolskaja A.; Bender H.G.; Frick M.

Role of single photon emission tomography with ^99mTc-MIBI in diagnosis of metastatic widespread in breast cancer
pp. 19-20(2)
Authors: Riannel J.E.; Slonimskaya E.M.; Barysheva E.V.; Musabaeva L.I.; Velichko S.A.; Ussov W.Y.

Monitoring the efficacy of primary chemotherapy for breast cancer using breast scintigraphy and immunocytochemical bone marrow screening
pp. 20-20(1)
Authors: Sommer H.; Tilling R.; Braun S.; Proehl-Steimer B.; Kandziora C.; Frauenklinik I.

Scintimammography & MR mammography in assessing palpable breast masses and recurrent tumour
pp. 20-20(1)
Authors: Fenlon H.M.; Phelan N.C.; O'Sullivan P.; Tierney S.; Gorey T.F.; Ennis J.T.

Tc-99m-sestamibi scintimammography for the evaluation of breast malignancies
pp. 20-20(1)
Authors: Pappo I.; Horne T.; Horn Y.; Orda R.

Evaluation of breast cancer utilizing proton magnetic resonance spectroscopy (MRS)
pp. 20-20(1)
Authors: Julka P.K.; Jagannathan N.R.; Singh M.; Raghunathan P.; Coshic O.; Rath G.K.

The determination of tissue polypeptide antigen (TPA) in follow-up of breast cancer
pp. 20-21(2)
Authors: Findeisen R.; Deutschmann K.; Richter B.; Albrecht S.; Distler W.

Determination of c-erbB-2 protein in sera from primary breast cancer patients
pp. 21-21(1)
Author: Imoto S.

Tumor proliferative activity evaluated with thymidine labelling index predicts response to adjuvant chemotherapy
pp. 21-21(1)
Authors: Pronzato P.; Sertoli M.R.; Venturini M.; Del Mastro L.; Queirolo P.; Vigani A.; Rosso R.

A different P53 genotype predicts major response to antracycline or paclitaxel based neoadjuvant therapy in breast cancer
pp. 21-21(1)
Authors: Kandioler-Eckersberger D.; Taucher S.; Rudas M.; Gebhard B.; Grunberger T.; Gnant M.; Steger G.; Jakesz R.

Prognostic significance of vascular tumor emboli in 1518 breast carcinoma patients with small tumor size (lt;3 cm)
pp. 21-21(1)
Authors: Pierga J.-Y.; Vincent-Salomon A.; Cousineau M.; Zafrani B.; Asselain B.; Dieras V.; Sastre-Garau X.; Pouillart P.

Prognostic parameters in node negative breast cancer receiving adjuvant CMF: Analysis of a randomized trial with emphasis on p53 and HER 2 neu
pp. 22-22(1)
Authors: Hardy-Bessard A.C.; De Roquancourt A.; Cottu P.H.; De Cremoux P.; Marty M.; Espie M.

Apoptosis and related proteins in ductal breast carcinoma
pp. 22-22(1)
Authors: Makar A.; Van Leuven H.; Declerq S.; Beelaerts W.; Gerris J.; Kockx M.

Prognostic value of vascular endothelial growth factor protein in node-negative breast cancer
pp. 22-22(1)
Authors: Linderholm B.; Tavelin B.; Grankvist K.; Henriksson R.

Expression of hepatocyte growth factor/scatter factor in primary breast cancer
pp. 22-22(1)
Authors: Venizelos B.; Blair P.; Holland J.; Freemont A.F.; Bundred N.J.

CIP-1 protein expression in node-positive breast cancer patients
pp. 22-23(2)
Authors: Hupperets P.; Thunnissen E.; Peterse J.; Schouten H.

Multivariate prognostic index with emphasis on proliferation adds specificity to standard prognostic factors in operable breast cancer
pp. 23-23(1)
Authors: Huovinen R.; Collan Y.; Kuopio T.; Kronqvist P.; Manttari S.; Jalava P.; Juntti L.

Immunohistochemical detection of tumor cells in lymph nodes and bone marrow aspirates in node negative (N0) breast cancer (BC)
pp. 23-23(1)
Authors: Gerber B.; Krause A.; Rohde E.; Richter D.; Friese K.

Prognostic value of plasminogenaktivator inhibitor type 1 and 2 in primary breast cancer
pp. 23-23(1)
Authors: Fersis N.; Krainick U.; Frise H.; Thron S.; Szekelyi M.; Wittmann G.; Wallwiener D.; Bastert G.

Prognostic factors predictive of lymph node status in breast cancer
pp. 23-23(1)
Authors: Distante V.; Bianchi S.; Simoncini R.; Petrolo A.; Valiani A.; Orzalesi L.; Cataliotti L.

Urokinase plasminogen activator and cathepsin D in micrometastatic cells of patients with primary breast cancer
pp. 23-24(2)
Authors: Solomayer E.-F.; Diel I.J.; Gollan C.; Meyberg G.; Bode S.; Wallwiener D.; Bastert G.

Prognostic significance of mutant p53 in breast cancer patients
pp. 24-24(1)
Authors: Castiglione F.; Sarotto I.; Destefanis M.; Ricco M.T.; Porcile G.

Evaluation of bone marrow micrometastases as potential surrogate marker for efficacy of adjuvant treatment
pp. 24-24(1)
Authors: Braun S.; Kentenich C.R.M.; Janni W.; Hepp F.; de Waal J.; Sommer H.L.

Age is not a prognostic factor in breast cancer patients with combined losses of heterozygosity (LOH) in BRCA1 and BRCA2 regions
pp. 24-24(1)
Authors: Silva J.M.; Gonzalez R.; Dominguez G.; Garcia J.M.; Martinez G.; Navarro F.; Provencio M.; Espana P.; Bonilla F.

Tumorbiological factors (uPA, PAI-1) as selection criteria for adjuvant chemotherapy in axillary node-negative breast cancer patients
pp. 24-25(2)
Authors: Janicke F.; Thomssen C.; Harbeck N.; Prechtl A.; Berger U.; Ulm K.; Dettmar P.; Pache L.; Schmitt M.; Graeff H.

15 year update of the naples GUN trial of adjuvant breast cancer therapy: Evidence of interaction between c-erb-B2 expression and Tamoxifen efficacy
pp. 25-25(1)
Authors: Bianco A.R.; De Laurentiis M.; Carlomagno C.; Lauria R.; Petrella G.; Panico L.; Pettinato G.; Perrone F.; Gallo C.; Marinelli A.; De Placido S.

Locally advanced breast cancer (LABC): Prognostic variables affecting results
pp. 25-25(1)
Authors: Baldini E.; Gardin G.; Lionetto R.; Montanaro E.; Salvadori B.; Massa R.; Rosso R.; Conte P.F.

Prognostic value of estrogen receptor (ER) status in breast cancer patients with five or more axillary lymph nodes (LN) involved
pp. 25-25(1)
Authors: Estevez L.; Marcos B.; Casado V.; Robles L.; Andrade J.; San Roman J.M.; Rivas C.; Ageitos A.G.; Domine M.; Vicente J.; Lobo F.

Predictive parameters of response in primary CMF chemotherapy of breast cancer
pp. 25-25(1)
Authors: Escobedo A.; Moreno A.; Loveras B.; Figueras A.; Riu F.; Gimenez C.; Prieto L.

Effectiveness of postoperative radiotherapy in controling subclinical locoregional disease in breast cancer patients with positive axillary nodes
pp. 25-26(2)
Author: Korzeniowski S.

Lack of correlation between menstrual phase during operation and prognosis of premenopausal patients with early breast cancer in a randomized study of adjuvant chemo-endocrine therapy
pp. 26-26(1)
Authors: Nomura Y.; Takayama T.; Hagino Y.; Kataoka A.

Aesthetic results of the breast cancer conservative treatment in the lower quadrants
pp. 26-26(1)
Authors: Calabrese C.; Nannelli A.; Distante V.; Simoncini R.; Cataliotti L.

Is axillary lymph node dissection indicated for early stage breast cancer? A decision analysis
pp. 26-26(1)
Authors: Prosnitz L.R.; Parmigiani G.; Winer E.P.; Tebaldi C.; Iglehart J.D.; Berry D.A.

Sentinel lymph node biopsy in breast cancer - Which tumors are suitable?
pp. 26-27(2)
Authors: Reuhl T.; Markwardt J.; Haensch W.; Schlag P.M.

Minimally invasive surgery in wire-guided breast biopsy: Role of specimen mammography in predicting margins
pp. 27-27(1)
Authors: Sheridan C.P.; Fenlon H.M.; Tierney S.; Buckley D.; Codd M.B.; Ennis J.T.; Fitzpatrick J.M.; Gorey T.F.

First experience with the advanced breast biopsy instrumentation. A new system for stereotactic excisions of suspicious non-palpable breast lesions
pp. 27-27(1)
Authors: Zuber M.; Oertli D.; Muller D.; Marti W.R.; Kochli O.R.; Harder F.

Risk factors of local recurrence in women with ductal carcinoma in situ (DCIS) according to the treatment
pp. 27-27(1)
Authors: Auvray H.; Penault-Llorca F.; De Latour M.; Dauplat J.; Achard J.L.; Le Bouedec G.

Prospective risk adapted therapy of ductal in situ breast cancer
pp. 27-27(1)
Authors: Buehner M.; Folger M.; Dresel V.; Lang N.; Tulusan A.H.

Adjuvant radiotherapy has no benefit after primary breast cancer treatment in selected postmenopausal patients
pp. 31-31(1)
Authors: Gruenberger T.; Gorlitzer M.; Mittlboeck M.; Axner I.; Rudas M.; Kandioler D.; Taucher S.; Gebhard B.; Steger G.; Gnant M.; Jakesz R.

Sector resection with or without postoperative radiotherapy for sage I breast cancer. Long term results and definition of a subgroup not requiering radiotherapy
pp. 31-31(1)
Authors: Liljegren G.; Holmberg L.; Adami H.O.; Bergh J.

Influence of radiotherapy on the dose intensity of CMF as adjuvant treatment
pp. 31-31(1)
Authors: Escobedo A.; Gil M.; Moreno F.; Llort G.; Pera J.

Neutron therapy in treating patients with breast cancer
pp. 31-31(1)
Authors: Slonimskaya E.M.; Musabaeva L.I.; Lisin V.A.; Shagiakhmetova R.A.

Initial versus delayed radiotherapy combined with continuous 5-fluorouracile (F), cyclophosphamide (C) and doxorubicine (A) in inflammatory breast cancer (IBC)
pp. 32-32(1)
Authors: Palangie T.; Asselain B.; Campana F.; Beuzeboc P.; Dieras V.; Dorval T.; Jouve M.; Pierga J.-Y.; Scholl S.; Pouillart P.

Radiotherapy and concomitant chemo or ormonotherapy in early stage breast cancer: Acute and late local toxicity
pp. 32-32(1)
Authors: Valli M.C.; Cazzaniga L.F.; Bossi A.; Cosentino D.; Scandolaro L.

Inflammatory breast cancer: Chemotherapy and concommittant radiotherapy
pp. 32-32(1)
Authors: Tubiana-Mathieu N.; Lejeune C.; Bonnier P.; Genet D.; Clavere P.; Berdah J.F.; Delaby F.; Adjadj D.; Roullet B.; Muracciole X.; Rhein B.; Juin P.; Piana L.

Breast cancer: External beam radiotherapy and interstitial implantation - 10-Year clinical results
pp. 32-32(1)
Authors: Hammer J.; Track C.; Seewald D.H.; Zoidl J.P.; Labeck W.; Putz E.; Gruy B.

Adjuvant chemotherapy of patients with primary breast cancer (PABC) by fluorouracil (5-FU)
pp. 32-32(1)
Authors: Hazova T.V.; Koritova L.I.; Ilyin N.V.

The effect of preoperative irradiation therapy and adjuvant chemotherapy for clinical stage III breast cancer
pp. 33-33(1)
Authors: Mudenas A.; Spikalovas V.; Bruzas S.; Luksyte A.; Kurtinaitis J.

5-Year results of combined modality approach in locally advanced breast cancer (LABC). Analysis of prognostic factors
pp. 33-33(1)
Authors: Zambetti M.; Quattrone P.; Verderio P.; Oriana S.; Valagussa P.; Terenziani M.; Zucali R.; Bonadonna G.

Epirubicin (EPI) and vinorelbine (VNR): A new promising combination for primary systemic chemotherapy for breast cancer
pp. 33-33(1)
Authors: Nistico C.; de Matteis A.; Valenza R.; Quattrocchio D.; Garufi C.; Maiorino A.; Cremonesi M.; Rossi E.; Agostara B.; Lazzaro B.; Borzacchini A.M.; D'Ottavio A.M.; Mencacci R.; Terzoli E.

Meta-analysis of dose intensity in breast cancer neoadjuvant chemotherapy (1985-1997)
pp. 33-33(1)
Author: Shparyk Y.

Neoadjuvant therapy in stage II with Tgt;4CM and stage III breast cancer
pp. 33-33(1)
Authors: Enomoto K.; Ikeda T.; Matsui A.; Kitajima M.; Koh J.; Masamura S.; Kinoshita T.; Ishikawa H.

Evaluation of clinical response to neoadjuvant chemotherapy of large primary breast tumours (gt;3.5 CM) and correlation with magnetic resonance imaging
pp. 34-34(1)
Authors: Cocquyt V.; Villeirs G.; Depypere H.T.; Van den Broecke R.; Serreyn R.; Mortier M.; Van Belle S.

Neoadjuvant chemotherapy with paclitaxel (P) in breast cancer, T 34, N+ M0
pp. 34-34(1)
Authors: Botto H.G.; Botto M.E.; Otegui-Araoz M.L.

Multimodality therapy of 128 patients with locally advanced breast cancer in the era of mammography screening using standard FEC-prognostic and therapeutic implications
pp. 34-34(1)
Authors: Karlsson Y.; Malmstrom P.; Hatschek T.; Fornander T.; Soderberg M.; Bengtsson N.-O.; Jansson T.; Sjoberg S.; Bergh J.

7-Year follow-up results of preoperative CMFAV in complex treatment of patients with locally advanced breast cancer
pp. 34-34(1)
Authors: Letyagin V.; Shomova M.; Visotskaya I.; Pogodina E.; Bogatyrev V.; Ivanov V.

Primary chemotherapy in conservative treatment of stage II breast cancer patients
pp. 34-34(1)
Authors: Ostapenko V.; Pipiriene T.; Valuckas K.

Three new highly active cisplatin-containing combinations in locally-advanced (stage III) and locally-recurrent breast carcinoma. A phase II randomized study
pp. 35-35(1)
Authors: Bisagni G.; Cocconi G.; Ceci G.; Di Blasio B.; De Lisi V.; Passalacqua R.; Zadro A.; Boni C.; Morandi P.; Savoldi L.

Neoadjuvant chemotherapy in locally-advanced breast cancer: A preliminary report
pp. 35-35(1)
Authors: Turkish Oncology Study Group; Baltali E.; Firat D.; Oncel N.; Onat D.A.; Atahan i.L.; Buyukunal E.; Celik I.; Aktan G.

Using high doses of 5-fluorouracil in patients with breast cancer: 3-Year results of the treatment
pp. 35-35(1)
Authors: Slonimskaya E.M.; Kolesnikov S.V.; Garbukov E.Y.; Karaseyova V.V.; Zharkova O.V.

Comparison of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF-chemotherapy versus tamoxifen in node positive breast cancer. An up-date of the German adjuvant breast cancer group (GABG) trial
pp. 35-35(1)
Authors: Kaufmann I.M.; Jonat W.; von Minckwitz G.; Schmid H.; Kleine W.; Melchert F.; Ulmer M.U.; Stosiek U.; Trams G.; Balzer J.; Caffier H.

Dose effect of epirubicin in amenorrhea induced by chemotherapy for breast cancer
pp. 35-36(2)
Authors: Weber B.; Luporsi E.

High dose epirubicin and cyclophosphamide (EC) vs cyclophosphamide, methotrexate, fluorouracil (CMF) as adjuvant chemotherapy in high risk premenopausal breast cancer patients (PTS). A prospective randomized trial
pp. 36-36(1)
Authors: Galligioni E.; Cetto G.; Nascimben O.; Buonadonna A.; Crivellari D.; Molino A.; Veronesi A.; Graiff C.; Barni S.; Puccetti C.; Ferrazzi E.; Recaldin E.; Sava C.; Saracchini S.; Sacco C.

Feasibility of docetaxel (D)-containing regimens in the adjuvant treatment (AT) of breast cancer (BC)
pp. 36-36(1)
Authors: Di Leo A.; Crown J.; Nogaret J.M.; Duffy K.; Bartholomeus S.; Rowan S.; Dolci S.; O'Higgins N.; Riva A.; Piccart M.J.

Epirubicin as a single agent in comparison to CMF in adjuvant therapy of stage I and II breast cancer
pp. 36-36(1)
Authors: Colozza M.; Bisagni G.; Mosconi A.M.; Gori S.; Boni C.; Bian A.R.; Sabbatini R.; Frassoldati A.; Passalacqua R.; Rodino C.; Rondini E.; Algeri R.; Di Sarra S.; Bacchi M.; Tonato M.; Cocconi G.

Adjuvant therapy of primary breast cancer with doxorubicin vs. pirarubicin in combination with cyclophosphamide and 5-fluorouracil (FAC vs. FPC)
pp. 36-37(2)
Authors: Budisic Z.; Podolski P.; Markulin-Grgic L.; Santek F.; Kosovel E.

Adjuvant chemotherapy of primary breast cancer: 20 Years follow up
pp. 37-37(1)
Authors: Gad-El-Mawla N.; Gaafar R.; El-Zawahri H.; Abdel-Wareth A.; Ali N.M.

Reduction of metastases in breast cancer patients by adjuvant bisphosphonate treatment
pp. 37-37(1)
Authors: Diel I.J.; Solomayer E.-F.; Gollan C.; Wallwiener D.; Bastert G.

Does the mobilization regimen influence peripheral blood stem cell (PBSC) tumor contamination in early breast cancer patients that undergo high dose chemotherapy? A comparison of chemotherapy plus G-CSF vs G-CSF mobilized PBSC
pp. 37-37(1)
Authors: Peccatori F.; Cinieri S.; Bertolini F.; Cocorocchio E.; Ferrucci F.; Lanza A.; Agazzi A.; Corsini C.; della Cuna G.R.; Martinelli G.

High-dose chemotherapy with stem cell support in breast cancer: Does cyclophosphamide alter high-dose thiotepa pharmacokinetics?
pp. 37-37(1)
Authors: Dobrovolskaja A.; Nitz U.; Frick M.; Bender H.G.; Burk M.

Low morbidity and no mortality of high-dose cyclophosphamide, thiotepa and mitoxantrone plus autologous peripheral blood stem cell support for high-risk breast cancer patients
pp. 38-38(1)
Authors: Kroger N.; Kruger W.H.; Gieseking F.; Jaenicke F.; Schultze W.; Fuss H.; Mobus V.; Konigsmann M.; Berdel W.E.; Schafer-Eckert K.; Wandt H.; Metzner B.; Illiger H.J.; Frickhofen N.; Wulf G.; Wormann B.; Kolbe K.; Hossfeld D.K.; Maas H.; Jonat W.; Zander A.R.

Gene replacement used as adjuvant therapy in primary chemoresistant adenocarcinoma of the breast
pp. 38-38(1)
Authors: Giannios J.; Ioannidou-Mouzaka L.

Therapeutic efficiency of DNA-conjugated doxorubicin in chemotherapy of advanced stages of primary breast cancer
pp. 38-38(1)
Authors: Melnikov D.Y.; Baykin Y.B.

Long-term intraarterial chemotherapy for breast cancer
pp. 38-38(1)
Authors: Yugrinov O.G.; Telny V.V.; Tarutinov V.I.; Sklyar S.Y.

Randomized trials to assess the effectivity of tamoxifen as adjuvant treatment in node-negative and receptor positive breast cancer. The Heidelberg II and GABG II trials
pp. 39-39(1)
Authors: von Minckwitz G.; Kaufmann M.; Schmid H.; Kleine W.; Brunnert K.; Ulmer M.U.; Stosiek U.; Mahike M.; Mehrpohl H.G.; Neises M.; Baltzer J.

Endometrial cancer and endometrial hyperplasia in postmenopausal women with breast cancer
pp. 39-39(1)
Authors: Montzka P.; Schultze-Mosgau A.; Bauer O.; Diedrich K.

Preliminary report; Zoladex and tamoxifen as adjuvant treatment in premenopausal breast cancer
pp. 39-39(1)
Authors: CRC Breast Cancer Trials Group S.B.C.T.G.; Houghton J.

Arimidex, tamoxifen alone or in combination (ATAC) adjuvant trial in post-menopausal breast cancer
pp. 39-39(1)
Authors: Baum M.; Houghton J.

&unknown;Arimidex&unknown; (anastrozole): Lack of interactions with tamoxifen, antipyrine, cimetidine and warfarin
pp. 39-40(2)
Authors: Arimidex Study Group; Dowsett M.; Yates R.; Wong Y.W.J.

Randomized trial of two versus four years of adjuvant tamoxifen (AT) for postmenopausal women with node positive breast cancer
pp. 40-40(1)
Authors: A cooperative oncologic group; Gallen M.; Alonso C.; Ojeda B.; Viladiu P.; Beltran M.; Borras J.; Pelegri A.; Tusquets I.; Barnadas A.; Arcusa A.; Bastus R.; Balil A.; Batiste-Alentorn E.; Boleda M.; Badia M.A.; Garau I.; Guash I.

Adjuvant high-dose medroxyprogesterone acetate (HD-MPA) for early breast cancer. 13 Years update of a multicenter randomized trial
pp. 40-40(1)
Authors: Focan C.; Beauduin M.; Salamon E.; de Greve J.; de Wasch G.; Lobelle J.P.; Majois F.; Tagnon A.; Tytgat J.; Van Belle S.; Vandervellen R.; Vindevoghel A.

What threshold for adjuvant tamoxifen in older breast cancer patients? A decision analysis
pp. 40-40(1)
Authors: Extermann M.; Balducci L.; Lyman G.

Adjuvant chemotherapy plus alternated hormonal therapy (AVCF-TM) for HR+ N+ breast cancer: 13-Year results of a randomized phase III trial
pp. 40-41(2)
Authors: Di Palma M.; Delaloge S.; Guerin S.; Fargeot P.; Conroy T.; Chollet P.; Misset J.L.

Inhibition of Tamoxifen's therapeutic benefit by Tangeretin in mammary cancer
pp. 41-41(1)
Authors: Depypere H.T.; Bracke M.E.; Mareel M.M.; Nuytinck M.; Vennekens K.; Serreyn R.

A lack of evidence for the genotoxicity of tamoxifen and toremifene in the human endometrium
pp. 41-41(1)
Authors: Carmichael P.L.; Neven P.; Sardar S.; Van Hoof I.; Ugwumadu A.; Bourne T.; Tomas E.; Hellberg P.; Hewer A.; Davis W.; Phillips D.H.

The &unknown;ZEBRA&unknown; study: &unknown;Zoladex&unknown; (goserelin) vs CMF as adjuvant therapy in the management of node positive stage II breast cancer in pre/peri-menopausal women aged 50 years or less
pp. 41-41(1)
Authors: Jonat W.; Kaufmann M.; Blamey R.; Sheldon T.

Assessement of changes in life quality of breast cancer patients under adjuvant CMF-chemotherapy by means of the EORTC QLQ-C30
pp. 41-42(2)
Authors: Rensing K.; Stockhausen L.V.; Wallwiener D.; Grischke E.-M.; Bastert G.

Scalp cooling system (Thairapy system) in the prevention of alopecia in adjuvant CMF chemotherapy for breast cancer
pp. 42-42(1)
Authors: Fried G.; Kuten A.; Vizel B.; Drumea K.; Haim N.

The role of nurse counsellor support groups for women diagnosed with breast cancer at hunter breast screen
pp. 42-42(1)
Authors: Rees B.; Kelly K.; Forbes J.